業績（筆頭著者英文論文）

First author 英文論文

  1. Accumulation of CD56+ CD16- natural killer cells in response to preoperative chemotherapy for breast cancer. World J Oncol 15:682-94, 2024.
    この論文は、乳癌術前化学療法後の末梢血NK細胞のサブセットの変化をみたものです。術前化学療法によって腫瘍免疫が活性化され腫瘍縮小、生存効果の関与していることは既に知られていますが、本研究では 術前化療後のCD56+ CD16- NKサブセットの増加が腫瘍免疫の活性化と治療効果増強に関与する可能性が示唆されています。
  2. Impact of complex apoptotic signaling pathways on cancer cell sensitivity to therapy. Cancers (Basel) 16: 984, 2024.
    この論文は、抗がん剤によるがん細胞の細胞死の分子機構と治療効果増強への展望をレビューしたものです。がん細胞の細胞死にはアポトーシスと非アポトーシスの形態がありますが、それぞれの細胞死の分子伝達機序とクロストーク、標的治療、抗がん剤耐性の克服、腫瘍免疫への関与等について述べられています。
  1. Outcomes in patients with non-invasive breast carcinoma. Cancer Rep (Hoboken) 6:e1768, 2023.
  2. Breast cancer recurrence and survival rates in patients who underwent breast-conserving surgery under non-mechanically ventilated anesthesia. Cancer Rep (Hoboken) 6:e1643, 2023.
  3. Current status and prospects of anesthesia and breast cancer: Does anesthetic technique affect recurrence and survival rates in breast cancer surgery? Front Oncol 12:795864, 2022.
  4. Current and future therapies for immunogenic cell death and related molecules to potentially cure primary breast cancer. Cancers (Basel) 13:4756, 2021.
  5. Reconsidering the meaning of curing primary breast cancer as a systemic disease. Front Oncol 11: 639420, 2021.
  6. Clinical perspectives in addressing unsolved issues in (neo)adjuvant therapy for primary breast cancer. Cancers (Basel) 13: 926, 2021.
  7. Immune factors associated with the pathological and therapeutic effects of preoperative chemotherapy in patients with breast cancer. Transl Oncol 14:100927, 2021.
  8. Outpatient breast-conserving surgery for breast cancer: Use of local and intravenous anesthesia and/or sedation may reduce recurrence and improve survival. Ann Med Surg (Lond) 60: 365-71, 2020.
  9. The persisting complexity of relationships between anesthetic techniques and cancer recurrence in oncological surgery. Int J Surg 81: 98-9, 2020.
  10. Anesthetic techniques and recurrence of breast cancer: Unanswered questions. Gland Surg 9: 490-94, 2020.
  11. Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol 46:77-84, 2020.
  12. A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients. Cancer Immunol Immunother 68:577-85, 2019.
  13. Outcomes of outpatient breast cancer surgery at a private breast clinic. Breast J 24:628-32, 2018.
  14. Anesthetic technique for cancer surgery: Harm or benefit for cancer recurrence? Eur J Surg Oncol 44:557-8, 2018.
  15. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. J Transl Med 16:8, 2018.
  16. Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast cancer patients. Clin Transl Med 6:34, 2017.
  17. Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle. Cancer Metastasis Rev 36:159-77, 2017.
  18. Cancer immunoediting from immune surveillance to immune escape 121:1-14, 2007.
  19. Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology 121:149-57, 2007.
  20. Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. Lancet Oncol 7:1006-16, 2006.
  21. The role of apoptosis in cancer cell survival and therapeutic outcome. Cancer Biol Ther 5:1429-42, 2006.
  22. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Therapy 14:1-11, 2007.
  23. Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity. Clin Exp Immunol 146:189-96, 2006.
  24. Cancer immunosuppression and autoimmune disease: Beyond immunosuppressive networks for tumor immunity. Immunology 119:254-64, 2006.
  25. Extranuclear expression of hormone receptors in primary breast cancer. Ann Oncol 17:1213-20, 2006.
  26. Potential role of HER-2 in primary breast tumor with bone metastasis. Oncol Rep 15:1477-84, 2006.
  27. Tumor-driven evolution of immunosuppressive network during malignant progression. Cancer Res 66:5527-36, 2006.
  28. The role of apoptotic or nonapoptotic cell death in determining cellular response to anticancer treatment. Eur J Surg Oncol 32:269-77, 2006.
  29. Regulation and interplay of apoptotic and nonapoptotic cell death. J Pathol 208:319-26, 2006.
  30. Role of the unfolded protein response in cell death. Apoptosis 11:5-13, 2006.
  31. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol Ther 4:924-33, 2005.
  32. Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol 21:1-9, 2005.
  33. Caspase-dependent and -independent cell death pathways after DNA damage. Oncol Rep 14:595-9, 2005.
  34. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 333:336-43, 2005.
  35. Assay directed chemotherapy: clinical benefit remains unclear. Cancer Treat Rev 31:151-4, 2005.
  36. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells. Cancer 103:2199-207, 2005.
  37. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer. Int J Oncol 26:1025-31, 2005.
  38. Chemosensitization by STI571 targeting the PDGF/PDGFR-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer 103:1800-9, 2005.
  39. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 103:1551-60, 2005.
  40. Current and future roles of neoadjuvant chemotherapy in operable breast cancer. Clin Breast Cancer 6: 223-32, 2005.
  41. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 101:2491-502, 2004.
  42. Bax is an important determinant for radiation sensitivity in esophageal carcinoma cells. Int J Mol Med 14:697-706, 2004.
  43. Preclinical evaluation of antisense Bcl-2 as a chemosensitizer for patients with gastric carcinoma. Cancer 101:2177-86, 2004.
  44. The role of FasL and TGF-β in tumor progression; Molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 100:2281-91, 2004.
  45. Multidisciplinary approach to cancer treatment: A model for breast cancer treatment at the M.D. Anderson Cancer Center. Int J Clin Oncol 9:356-63, 2004.
  46. Neoadjuvant chemotherapy for local advanced breast cancer with Stage IIIB. Oncol Rep 11:1265-72, 2004.
  47. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer. Int J Oncol 24:5-17, 2004.
  48. Changes in therapy for solid tumors: Potential for overcoming drug resistance in vivo with molecular targeting agents. Surgery Today 34:293-303, 2004.
  49. Chemosensitivity testing for gastrointestinal cancer: survival benefit potential and limitations. Anti-Cancer Drugs 14:715-23, 2003.
  50. Death receptor-dependent and -independent pathways in anticancer drug-induced apoptosis of breast cancer cells. Oncol Rep 10:1925-30, 2003.
  51. Clinical relevance of meta-analysis of survival benefit when deciding treatment of adjuvant chemotherapy in gastric cancer. Anticancer Res 23:1843-6, 2003.
  52. Factors that influence the incidence of microscopic carcinoma in frozen and preserved specimens from patients with breast carcinoma after breast-conserving surgery. Oncol Rep 10:1321-28, 2003.
  53. Effects of introduction of dThdPase cDNA on sensitivity to 5’-deoxy-5-fluorouridine and tumor angiogenesis. Int J Oncol 22:835-41, 2003.
  54. Effect of Bcl-2 antisense oligonucleotides on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma. Int J Mol Med 11:799-804, 2003.
  55. Feasibility and therapeutic efficacy of weekly 1-hour low-dose paclitaxel infusion for relapsed breast cancer. Oncol Rep 10:145-50, 2003.
  56. Inducing cancer cell death by targeting transcription factors. Anti-Cancer Drugs 14:3-11, 2003.
  57. Current status of the molecular mechanisms of anticancer drug-induced apoptosis -The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 50:343-52, 2002.
  58. Adjuvant therapy for colorectal cancer. Anticancer Res 22:2413-8, 2002.
  59. Utility of techinetium-99m methoxyisobutylisonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer. Breast Cancer 9:240-7, 2002.
  60. Mechanism(s) of antitumor action in protracted infusion of low-dose 5-fluorouracil and cisplatin in gastric carcinoma. Int J Oncol 20:549-55, 2002.
  61. Current status and future perspectives of post-operative adjuvant therapy for gastric carcinoma. Anticancer Res 22:283-90, 2002.
  62. The role of HER-2 oncoprotein in drug-sensitivity in breast cancer. Oncol Rep 9:3-9, 2002.
  63. Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer. Int J Oncol 18:363-7, 2001.
  64. A phase II trial of mitomycin C, 5’-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action. Oncol Rep 8:597-603, 2001.
  65. An analysis of relapsed breast cancer in patients previously treated with breast conserving surgery. Breast Cancer 8:146-52, 2001.
  66. Effect of inhibitors of cysteine and serine proteases in anticancer drug-induced apoptosis in gastric cancer cells. Int J Oncol 18:1227-32, 2001.
  67. Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer. Oncol Rep 8:1171-6, 2001.
  68. A pitfall in the survival benefit of adjuvant chemotherapy for node- and hormone receptor-positive patients with breast cancer: The paradoxical role of Bcl-2 oncoprotein. Int J Oncol 19:1075-80, 2001.
  69. Significance of lymphoscintigraphic mapping with Tc-99m human serum albumin and tin colloid in sentinel lymph node biopsy in breast cancer. Int J Oncol 19:991-6, 2001.
  70. Enhancement of chemotherapeutic agents induced-apoptosis associated with activation of c-Jun N-terminal kinase 1 and caspase 3 in bax-transfected gastric cancer cells. Anticancer Res 20:439-44, 2000.
  71. An analysis of the therapeutic efficacy of protracted infusion of low dose of 5-fluorouracil and cisplatin to advanced gastric cancer. J Infect Chemother 6:222-8, 2000.
  72. Activation and the interaction of proapoptotic genes in modulating sensitivity to anticancer drugs in gastric cancer cells. Int J Oncol 15:751-6, 1999.
  73. A phase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer. Int J Oncol 15:921-6, 1999.
  74. Introduction of gadd153 gene into gastric cancer cells can modulate sensitivity to anticancer drugs in association with apoptosis. Anticancer Res 19:1779-86, 1999.
  75. Expression and relationship between topoisomerase I and II alpha genes in tumors and normal tissues in esophageal, gastric and colon cancers. Anticancer Res 19:5393-8, 1999.
  76. Taxotere activates transcription factor AP-1 in association with cell death in gastric cancer cell lines. Anticancer Res 19:5399-406, 1999.
  77. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA binding activity, and formation of Jun/Fos family dimmers, and their association with internucleosomal DNA ladders after treatment with VM-26. Cancer Res 54:4958-66, 1994.
  78. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50:760-6, 1992.
  79. Clinical significance of P-glycoprotein expression analyzed by immunohistochemical staining in cancer tissues. Jpn J Surg (Surgery Today) 21:590-3, 1991.
  80. mRNA expression of topoisomerase II in human tumors and normal tissues. Jpn J Surg (Surgery Today) 21:587-9, 1991.
  81. Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Res 11:429-32, 1991.
  82. Factors contributing to adriamycin sensitivity in human xenografts tumors: the relationship between expression of the MDR1, GST-pi and topoisomerase II genes and tumor sensitivity to adriamycin. Anticancer Res 12:241-6, 1991.
  83. Expression of the multidrug resistance gene in human tumors. Hiroshima J Med Sci 3:71-7, 1990.
  84. Prediction of the resistance of human tumors to adriamycin by chemosensitivity tests and DNA analysis of the multidrug resistance gene. Jpn J Surg (Surgery Today) 20:192-6, 1990.